{"id":"arxiv:2005.02182","kind":"article","title":"Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease","authors":["Alok Joshi","Da-Hui Wang","Steven Watterson","Paula L. McClean","Chandan K. Behera","Trevor Sharp","KongFatt Wong-Lin"],"author_count":7,"year":2020,"published":"2020-05-05","venue":"Neuropharmacology","cited_by":22,"doi":"10.1016/j.neuropharm.2020.108118","arxiv_id":"2005.02182","nct_id":null,"source_url":"https://arxiv.org/abs/2005.02182","archive_url":"https://space-kitty.com/papers/arxiv:2005.02182","updated":"2020-05-27","pmid":null,"pmcid":null,"openalex_id":"W3023504426","pdf_url":"https://arxiv.org/pdf/2005.02182","abstract":"Alzheimer's disease (AD) is an age-specific neurodegenerative disease that compromises cognitive functioning and impacts the quality of life of an individual. Pathologically, AD is characterised by abnormal accumulation of beta-amyloid (A$β$) and hyperphosphorylated tau protein. Despite research advances over the last few decades, there is currently still no cure for AD. Although, medications are available to control some behavioural symptoms and slow the disease's progression, most prescribed medications are based on cholinesterase inhibitors. Over the last decade, there has been increased attention towards novel drugs, targeting alternative neurotransmitter pathways, particularly those targeting serotonergic (5-HT) system. In this review, we focused on 5-HT receptor (5-HTR) mediated signalling and drugs that target these receptors. These pathways regulate key proteins and kinases such as GSK-3 that are associated with abnormal levels of A$β$ and tau in AD. We then review computational studies related to 5-HT signalling pathways with the potential for providing deeper understanding of AD pathologies. In particular, we suggest that multiscale and multilevel modelling approaches could potentially provide new insights into AD mechanisms, and towards discovering novel 5-HTR based therapeutic targets.","abstract_license":"CC0-1.0 (arXiv descriptive metadata)","license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["q-bio.SC","q-bio.MN","q-bio.NC"],"details":null,"provenance":"arxiv","attribution":"Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}